Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer
Articolo
Data di Pubblicazione:
2020
Citazione:
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer / B, Duchemann; J, Remon; M, Naigeon; L, Mezquita; Ferrara, R; L, Cassard; Jm, Jouniaux; L, Boselli; J, Grivel; E, Auclin; A, Desnoyer; B, Besse; N, Chaput. - In: CANCERS. - ISSN 2072-6694. - 9:5(2020), pp. 1143-1161. [10.3390/cancers12123625]
Abstract:
Immune checkpoint inhibitors are now a cornerstone of treatment for non-small cell lung cancer (NSCLC). Tissue-based assays, such as Programmed cell death protein 1 (PD-L1) expression or mismatch repair deficiency/microsatellite instability (MMRD/MSI) status, are approved as treatment drivers in var …
Tipologia CRIS:
1.1.3. Articolo in Rivista - Editorial, Comment, Reply
Elenco autori:
B, Duchemann; J, Remon; M, Naigeon; L, Mezquita; Ferrara, R; L, Cassard; Jm, Jouniaux; L, Boselli; J, Grivel; E, Auclin; A, Desnoyer; B, Besse; N, Chaput
Link alla scheda completa:
Pubblicato in: